In a meta-analysis including selected large-scale cardiovascular outcome randomized placebo-controlled trials or their prespecified subgroup analyses, evaluating SGLT2 inhibitors for primary prevention of atherosclerotic CVD, SGLT2 inhibitors significantly reduced atherosclerotic MACEs in patients with both T2DM and CKD without established ASCVD [258]. Here, SLC5A2 is linked to chronic kidney disease.